Global Antibiotic Resistance Market Size, Share, Forecast Report, 2020-2027

The global Antibiotic Resistance market garnered revenue around USD XX Billion in 2019 and projected to reach USD 13 Billion in 2027, with at a compound annual growth rate of 5.9% throughout the estimate period from 2020 to 2027.

Antibiotic resistance occurs naturally, but the misuse of antibiotics in humans would increase the growth of antimicrobial resistance. Bacteria become resistant to the antibiotics that are designed to kill them. Increasing antibiotic-resistant infections and emergence of multi-drug resistant pathogens will enhance the growth of antibiotic resistance market. For instance, in 2016, approximately 49,000 people developed multi-drug resistant TB globally, and drug resistance is complicating the fight against HIV as well as malaria.

There is an extensive occurrence of antibiotic resistance among 5,00,000 people with suspected bacterial infections across 22 countries in the antibiotic resistance marker. As a result, increasing the occurrence of antibiotic resistance would drive the demand for the global antibiotic resistance market.

High medical costs. The cost of health care for patients suffering from resistant infections is higher than care for patients suffering from non-resistant infections due to the extended duration of illness, and increased usage of expensive drugs.

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Antibiotic Resistance market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Antibiotic Resistance market growth.

The global Antibiotic Resistance market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

Achaogen, Inc. (US)

Basilea Pharmaceutica Ltd. (Switzerland)

MELINTA THERAPEUTICS, INC. (US)

PARATEK therapeutics (US)

Seres Therapeutics (US)

Theravance Biopharma (UK)

Entasis Therapeutics (US)

Tetraphase Pharmaceuticals (US)

Nabriva Therapeutics plc (Ireland)

NEMESIS BIOSCIENCE LTD (UK)

Procarta Biosystems (England)

Allecra Therapeutics (US)

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

By Drug class

Cephalosporins:

Combination Therapies:

Tetracyclines:

Lipoglycopeptides:

Oxazolidinones:

Others:

By Disease

Complicated Urinary Tract Infection:



Blood Stream Infections:

Complicated Intra-Abdominal Infections:

Clostridium Difficile Infections:

Acute Bacterial Skin and Skin Structure Infections:

Hospital-Acquired Bacterial Pneumonia/Ventilator:

Community-Acquired Bacterial Pneumonia:

Others:

By Pathogen

Staphylococcus Aureus

Streptococcus Pneumoniae

Acinetobacter:

Enterococcus:

Hemophilus Influenzae:

Pseudomonas Aeruginosa:

Clostridium Difficile:

Pneumoniae:

Campylobacter:

Others:

By End-User



Hospitals & Clinics:

Research Organizations:

Others:

Regional Analysis and Forecast



Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:



� North America

? U.S.

? Canada

� Europe

? Germany

? U.K.

? Italy

? France

? Rest of EU

� Asia Pacific

? China

? India

? Japan

? Southeast Asia

? Rest of APAC

� Central & South America

? Brazil

? Argentina

? Rest of Central & South America

� Middle East and Africa

? UAE

? Saudi Arabia

? Rest of MEA